Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
INSM
#418
Insmed, Inc.
153.335
0
USD
+1.45%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
+1.45%
Changement Mensuel
+8.39%
Evolution sur 6 mois
-5.38%
Changement Annuel
-5.38%
Clôture Précédente
151.140
0
Open
153.290
0
Bid
Ask
Low
153.290
0
High
153.400
0
Volume
232
Marchés
Actions des Marchés US
Soins de Santé
INSM
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
103.04 M
118.9 M
136.41 M
148.49 M
181 M
215.55 M
—
Valuation ratios
Enterprise value
3.29 B
3.12 B
2.69 B
5.14 B
13.06 B
37.57 B
103.63 B
Price to earnings ratio
-11.05
-7.02
-4.91
-5.61
-12.39
-27.11
-81
Price to sales ratio
19.76
16.2
9.62
13.78
31.14
57.12
195.59
Price to cash flow ratio
-14.81
-8.41
-5.89
-7.84
-16.56
-37.04
-105.37
Price to book ratio
11.78
7.44
26.83
-12.67
39.69
46.87
80.61
Enterprise value to EBITDA ratio
-38.1
-36.39
-19.96
-37
-15.53
-38.07
-120.59
Profitability ratios
Return on assets %
-0.37
-0.35
-0.29
-0.56
-0.45
-0.56
-0.57
Return on equity %
-1.07
-1.06
-5.48
2.26
-3.2
-1.73
-3.68
Return on invested capital %
-495.59
-455.18
-438.7
-709.75
-852.72
-1 113.79
-1 180.67
Gross margin %
75.75
76.57
77.53
78.52
76.43
79.73
313.55
Operating margin %
-161.32
-199.03
-186.39
-232.51
-241.47
-205.59
-936.92
EBITDA margin %
-46.26
-36.77
-31.49
-35.1
-211.34
-160.3
-745.43
Net margin %
-178.87
-230.63
-196.26
-245.59
-251.24
-210.54
-960.35
Liquidity ratios
Quick ratio
4.83
5.7
6.33
3.75
5.12
3.54
19.66
Current ratio
5.24
6.19
6.69
4.12
5.45
3.83
21
Inventory turnover
1.02
0.76
0.81
0.86
0.94
1.07
1.09
Asset turnover
0.21
0.18
0.17
0.2
0.22
0.28
0.27
Solvency ratios
Debt to assets ratio
0.49
0.48
0.69
0.88
0.55
0.25
1.32
Debt to equity ratio
1.41
1.46
13.04
-3.54
3.93
0.76
13.01
Long term debt to total assets ratio
0.45
0.46
0.68
0.87
0.54
0.24
1.3
Long term debt to total equity ratio
1.29
1.38
12.79
-3.48
3.87
0.73
12.88
Per share metrics
Operating cash flow per share
-2.25
-3.24
-3.25
-3.82
-4.17
-4.7
-4.82
EBIT per share
-2.72
-3.35
-3.72
-5.05
-5.35
-6.26
-6.36
EBITDA per share
-0.78
-0.62
-0.63
-0.76
-4.69
-4.88
-4.98
Total debt per share
3.99
5.33
9.32
8.36
6.84
2.83
14.45
Cash per share
5.46
6.39
9.33
5.56
8.74
7.19
31.56
Net current asset value per share
6.38
7.47
10.35
6.62
9.89
9.02
36.89
Tangible book value per share
2.88
1.79
-0.95
-3.79
0.55
2.54
11.03
Working capital per share
5.16
6.26
8.8
5.01
8.07
6.66
29.59
Book value per share
2.83
3.66
0.71
-2.36
1.74
3.71
15.33
Nouvelles
RBC Capital relève l’objectif de cours d’Insmed grâce aux perspectives de Brinsupri
Raymond James initie la couverture d’Insmed avec une recommandation surperformance
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
H.C. Wainwright abaisse l’objectif de cours d’Insmed après l’échec d’un essai
Stifel maintient sa recommandation d’achat sur Insmed après l’échec de l’essai
Mizuho abaisse l’objectif de cours d’Insmed après l’échec d’un essai
Insmed Drug Misses Primary Goal, Program Axed - Insmed (NASDAQ:INSM)
Truist réitère sa recommandation sur Insmed après l’échec d’un essai
Valeurs en mouvement après clôture : Levi, Greenbrier, Aehr Test et autres
L’action Insmed chute après l’échec d’un essai sur l’hidrosadénite suppurée
Insmed abandonne son programme de traitement de l’hidradénite suppurée
Insmed: The Pipeline Is Catching Up To The Valuation (NASDAQ:INSM)